Seroprevalence of anti-HAV among patients with chronic viral liver disease.
OBJECTIVE
To investigate the current seroprevalence of hepatitis A virus (HAV) antibodies in patients with chronic viral liver disease in Korea. We also tried to identify the factors affecting the prevalence of HAV antibodies.


METHODS
We performed an analysis of the clinical records of 986 patients (mean age: 49 ± 9 years, 714 males/272 females) with chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infection who had undergone HAV antibody testing between January 2008 and December 2009.


RESULTS
The overall prevalence of IgG anti-HAV was 86.61% (854/986) in patients with chronic liver disease and was 88.13% (869/986) in age- and gender-matched patients from the Center for Health Promotion. The anti-HAV prevalence was 80.04% (405/506) in patients with chronic hepatitis B, 86.96% (20/23) in patients with chronic hepatitis C, 93.78% (422/450) in patients with HBV related liver cirrhosis, and 100% (7/7) in patients with HCV related liver cirrhosis. The anti-HAV prevalence according to the decade of age was as follows: 20s (6.67%), 30s (50.86%), 40s (92.29%), 50s (97.77%), and 60s (100%). The anti-HAV prevalence was significantly higher in patients older than 40 years compared with that in patients younger than 40 years of age. Multivariable analysis showed that age ≥ 40 years, female gender and metropolitan cities as the place of residence were independent risk factors for IgG anti-HAV seropositivity.


CONCLUSIONS
Most Korean patients with chronic liver disease and who are above 40 years of age have already been exposed to hepatitis A virus.
Division of Gastroenterology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 135-710, South Korea.
Hyun Chin
HC
Cho
Seung Woon
SW
Paik
Yu Jin
YJ
Kim
Moon Seok
MS
Choi
Joon Hyeok
JH
Lee
Kwang Cheol
KC
Koh
Byung Chul
BC
Yoo
Hee Jung
HJ
Son
Seon Woo
SW
Kim
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002908:Chronic Disease; D005260:Female; D006506:Hepatitis A / Q000276:immunology / Q000821:virology; D035922:Hepatitis A Antibodies / Q000276:immunology*; D030041:Hepatitis A virus / Q000276:immunology; D006509:Hepatitis B / Q000276:immunology / Q000821:virology; D006526:Hepatitis C / Q000276:immunology / Q000821:virology; D006801:Humans; D007723:Korea; D008107:Liver Diseases / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D016036:Seroepidemiologic Studies
D035922:Hepatitis A Antibodies
World J Gastroenterol. 2010 Mar 7;16(9):1115-8
20205283
Epidemiol Infect. 2001 Dec;127(3):469-73
11811880
Clin Infect Dis. 2004 Mar 1;38(5):705-15
14986256
Hepatogastroenterology. 2002 Mar-Apr;49(44):524-8
11995487
J Viral Hepat. 2000 May;7 Suppl 1:1-3
10870174
Vaccine. 1992;10 Suppl 1:S15-7
1335649
Eur J Gastroenterol Hepatol. 2007 Nov;19(11):923-6
18049159
N Engl J Med. 1998 Jan 29;338(5):286-90
9445408
Epidemiol Infect. 2004 Dec;132(6):1005-22
15635957
MMWR Morb Mortal Wkly Rep. 2003 Jun 20;52(24):565-7
12816107
Vaccine. 2003 Jun 2;21(19-20):2238-41
12744849
Ann Trop Med Parasitol. 1999 Oct;93(7):745-51
10715703
MMWR Morb Mortal Wkly Rep. 2003 Sep 5;52(35):844-5
12966361
Am J Epidemiol. 1985 Aug;122(2):226-33
3860002
N Engl J Med. 1999 Feb 25;340(8):595-602
10029643
J Infect Dis. 1998 Dec;178(6):1579-84
9815207
Dig Liver Dis. 2003 Jun;35(6):404-8
12868676
J Clin Gastroenterol. 2004 May-Jun;38(5):440-8
15100525
Lancet. 1998 May 30;351(9116):1643-9
9620732
Dig Dis Sci. 1986 Jan;31(1):109-11
3940818
Am J Gastroenterol. 1995 Feb;90(2):201-5
7847285
Vaccine. 2003 Jun 2;21(19-20):2224-33
12744847
J Infect Dis. 2003 Apr 15;187(8):1235-40
12696002
J Korean Med Sci. 2007 Apr;22(2):218-22
17449927
Ann Intern Med. 1989 May 15;110(10):838-9
2712463
J Infect Dis. 1995 Mar;171 Suppl 1:S2-8
7876643
Asian Pac J Allergy Immunol. 2004 Dec;22(4):237-42
15783137
MMWR Recomm Rep. 1999 Oct 1;48(RR-12):1-37
10543657
Can J Public Health. 2000 May-Jun;91(3):168-70
10927841
Korean J Gastroenterol. 2006 Feb;47(2):136-43
16498280
Am J Med. 2005 Oct;118 Suppl 10A:21S-27S
16271537
J Viral Hepat. 2008 Oct;15 Suppl 2:1-15
18837827